Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy for the treatment of primary peritoneal serous carcinoma: Results of a Chinese retrospective study

References

• Swerdlow M. Mesothelioma of the pelvic peritoneum resembling papillary cystadenocarcinoma of the ovary; case report. Am J Obstet Gynecol 1959;77:197–200.
   PubMed Web of Science ®Google Scholar
• Eltabbakh GH, Piver MS, Natarajan N, Mettlin CJ. Epidemiologic differences between women with extraovarian primary peritoneal carcinoma and women with epithelial ovarian cancer. Obstet Gynecol 1998;91:254–9.
   PubMed Web of Science ®Google Scholar
• Unal OU, Oztop I, Yazici O, Ozatli T, Inal A, Gunaydin Y, et al. Treatment and prognostic factors in primary peritoneal carcinoma: a multicenter study of the Anatolian Society of Medical Oncology (ASMO). Oncol Res Treat 2014;37:332–8.
   PubMedGoogle Scholar
• Bloss JD, Brady MF, Liao SY, Rocereto T, Partridge EE, Clarke-Pearson DL. Extraovarian peritoneal serous papillary carcinoma: a phase II trial of cisplatin and cyclophosphamide with comparison to a cohort with papillary serous ovarian carcinoma – a Gynecologic Oncology Group Study. Gynecol Oncol 2003;89:148–54.
   PubMed Web of Science ®Google Scholar
• Chen LM, Yamada SD, Fu YS, Baldwin RL, Karlan BY. Molecular similarities between primary peritoneal and primary ovarian carcinomas. Int J Gynecol Cancer 2003;13:749–55.
   PubMed Web of Science ®Google Scholar
• Cass I, Baldwin RL, Fasylova E, Fields AL, Klinger HP, Runowicz CD, et al. Allelotype of papillary serous peritoneal carcinomas. Gynecol Oncol 2001;82:69–76.
   PubMed Web of Science ®Google Scholar
• Fishman DA, Chilukuri K, Stack MS. Biochemical characterization of primary peritoneal carcinoma cell adhesion, migration, and proteinase activity. Gynecol Oncol 1997;67:193–9.
   PubMed Web of Science ®Google Scholar
• Goodman MT, Shvetsov YB. Incidence of ovarian, peritoneal, and fallopian tube carcinomas in the United States, 1995–2004. Cancer Epidemiol Biomarkers Prev 2009;18:132–9.
   PubMed Web of Science ®Google Scholar
• Dubernard G, Morice P, Rey A, Camatte S, Fourchotte V, Thoury A, et al. Prognosis of stage III or IV primary peritoneal serous papillary carcinoma. Eur J Surg Oncol 2004;30:976–81.
   PubMed Web of Science ®Google Scholar
• Pentheroudakis G, Pavlidis N. Serous papillary peritoneal carcinoma: unknown primary tumour, ovarian cancer counterpart or a distinct entity? A systematic review. Crit Rev Oncol Hematol 2010;75:27–42.
   PubMed Web of Science ®Google Scholar
• Gershenson DM, Bodurka DC, Lu KH, Nathan LC, Milojevic L, Wong KK, et al. Impact of age and primary disease site on outcome in women with low-grade serous carcinoma of the ovary or peritoneum: results of a large single-institution registry of a rare tumor. J Clin Oncol 2015;33:2675–82.
   PubMed Web of Science ®Google Scholar
• Chua TC, Moran BJ, Sugarbaker PH, Levine EA, Glehen O, Gilly FN, et al. Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Clin Oncol 2012;30:2449–56.
   PubMed Web of Science ®Google Scholar
• Sugarbaker PH. Five reasons why cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy must be regarded as the new standard of care for diffuse malignant peritoneal mesotheliomia. Ann Surg Oncol 2010;17:1710–12.
   PubMed Web of Science ®Google Scholar
• Maggiori L, Elias D. Curative treatment of colorectal peritoneal carcinomatosis: current status and future trends. Eur J Surg Oncol 2010;36:599–603.
   PubMed Web of Science ®Google Scholar
• Yarema RR, Ohorchak MA, Zubarev GP, Mylyan YP, Oliynyk YY, Zubarev MG, et al. Hyperthermic intraperitoneal chemoperfusion in combined treatment of locally advanced and disseminated gastric cancer: Results of a single-centre retrospective study. Int J Hyperthermia 2014;30:159–65.
   PubMed Web of Science ®Google Scholar
• Yang XJ, Huang CQ, Suo T, Mei LJ, Yang GL, Cheng FL, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase III randomized clinical trial. Ann Surg Oncol 2011;18:1575–81.
   PubMed Web of Science ®Google Scholar
• Arjona-Sanchez A, Munoz-Casares C, Ortega-Salas R, Casado-Adam A, Sanchez-Hidalgo JM, Rufian-Pena S. Long-term survival with peritoneal mucinous carcinomatosis from intraductal mucinous papillary pancreatic carcinoma treated with complete cytoreduction and hyperthermic intraperitoneal chemotherapy. Int J Hyperthermia 2014;30:408–11.
   PubMed Web of Science ®Google Scholar
• Huang CQ, Yang XJ, Yu Y, Wu HT, Liu Y, Yonemura Y, et al. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy improves survival for patients with peritoneal carcinomatosis from colorectal cancer: A phase II study from a Chinese center. PLoS One 2014;9:e108509.
   PubMed Web of Science ®Google Scholar
• Yang XJ, Li Y, al-shammaa Hassan AH, Yang GL, Liu SY, Lu YL, et al. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy improves survival in selected patients with peritoneal carcinomatosis from abdominal and pelvic malignancies: results of 21 cases. Ann Surg Oncol 2009;16:345–51.
   PubMed Web of Science ®Google Scholar
• Tang L, Duan R, Zhong YJ, Firestone RA, Hong YP, Li JG, et al. Synthesis, identification and in vivo studies of tumor-targeting agent peptide doxorubicin (PDOX) to treat peritoneal carcinomatosis of gastric cancer with similar efficacy but reduced toxicity. Mol Cancer 2014;13:44. doi: 10.1186/1476-4598-13-44.
   PubMed Web of Science ®Google Scholar
• Tang L, Mei LJ, Yang XJ, Huang CQ, Zhou YF, Yonemura Y, et al. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy improves survival of gastric cancer with peritoneal carcinomatosis: evidence from an experimental study. J Transl Med 2011;9:53.
   PubMed Web of Science ®Google Scholar
• Bloss JD, Liao SY, Buller RE, Manetta A, Berman ML, McMeekin S, et al. Extraovarian peritoneal serous papillary carcinoma: a case-control retrospective comparison to papillary adenocarcinoma of the ovary. Gynecol Oncol 1993;50:347–51.
   PubMed Web of Science ®Google Scholar
• Sugarbaker PH. Successful management of microscopic residual disease in large bowel cancer. Cancer Chemother Pharmacol 1999;43:15–25.
   PubMed Web of Science ®Google Scholar
• Sugarbaker PH. Peritonectomy procedures. Ann Surg 1995;221: 29–42.
   PubMed Web of Science ®Google Scholar
• Sugarbaker PH. Cytoreductive surgery and peri-operative intraperitoneal chemotherapy as a curative approach to pseudomyxoma peritonei syndrome. Eur J Surg Oncol 2001;27:239–43.
   PubMed Web of Science ®Google Scholar
• National Cancer Institute: Common Terminology Criteria for Adverse Events version 4.0. Available at: http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm.
   Google Scholar
• Liu Q, Lin JX, Shi QL, Wu B, Ma HH, Sun GQ. Primary peritoneal serous papillary carcinoma: a clinical and pathological study. Pathol Oncol Res 2011;17:713–19.
   PubMed Web of Science ®Google Scholar
• Halperin R, Zehavi S, Langer R, Hadas E, Bukovsky I, Schneider D. Primary peritoneal serous papillary carcinoma: a new epidemiologic trend? A matched-case comparison with ovarian serous papillary cancer. Int J Gynecol Cancer 2001;11:403–8.
   PubMed Web of Science ®Google Scholar
• Kawaguchi R, Tanase Y, Haruta S, Nagai A, Yoshida S, Furukawa N, et al. Paclitaxel plus carboplatin chemotherapy for primary peritoneal carcinoma: a study of 22 cases and comparison with stage III–IV ovarian serous carcinoma. Case Rep Oncol 2012;5:173–80.
   PubMedGoogle Scholar
• Zhang C, Li XP, Cui H, Shen DH, Wei LH. Advanced primary peritoneal carcinoma: clinicopathological and prognostic factor analyses. J Zhejiang Univ Sci B 2008;9:435–40.
   PubMed Web of Science ®Google Scholar
• Bakrin N, Gilly FN, Baratti D, Bereder JM, Quenet F, Lorimier G, et al. Primary peritoneal serous carcinoma treated by cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy. A multi-institutional study of 36 patients. Eur J Surg Oncol 2013;39:742–7.
   PubMed Web of Science ®Google Scholar
• Ifthikar AM, Rathod PS, Shruthi S, Pallavi VR, Shobha K, Shankaranand B, et al. Primary peritoneal carcinoma: regional cancer institute experience. Indian J Surg Oncol 2014;5:232–6.
   PubMedGoogle Scholar
• Ben-Baruch G, Sivan E, Moran O, Rizel S, Menczer J, Seidman DS. Primary peritoneal serous papillary carcinoma: a study of 25 cases and comparison with stage III–IV ovarian papillary serous carcinoma. Gynecol Oncol 1996 60:393–6.
   PubMed Web of Science ®Google Scholar
• Eltabbakh GH, Werness BA, Piver S, Blumenson LE. Prognostic factors in extraovarian primary peritoneal carcinoma. Gynecol Oncol 1998;71:230–9.
   PubMed Web of Science ®Google Scholar
• Piver MS, Eltabbakh GH, Hempling RE, Recio FO, Blumenson LE. Two sequential studies for primary peritoneal carcinoma: induction with weekly cisplatin followed by either cisplatin–doxorubicin–cyclophosphamide or paclitaxel–cisplatin. Gynecol Oncol 1997;67: 141–6.
   PubMed Web of Science ®Google Scholar
• Bakrin N, Bereder JM, Decullier E, Classe JM, Msika S, Lorimier G, et al. Peritoneal carcinomatosis treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for advanced ovarian carcinoma: a French multicentre retrospective cohort study of 566 patients. Eur J Surg Oncol 2013;39:1435–43.
   PubMed Web of Science ®Google Scholar
• Crane EK, Sun CC, Ramirez PT, Schmeler KM, Malpica A, Gershenson DM. The role of secondary cytoreduction in low-grade serous ovarian cancer or peritoneal cancer. Gynecol Oncol 2015; 136:25–9.
   PubMed Web of Science ®Google Scholar
• Sugarbaker PH. Peritoneum as the first-line of defense in carcinomatosis. J Surg Oncol 2007;95:93–6.
   PubMed Web of Science ®Google Scholar
• Altaras MM, Aviram R, Cohen I, Cordoba M, Weiss E, Beyth Y, et al. Primary peritoneal papillary serous adenocarcinoma: clinical and management aspects. Gynecol Oncol 1991;40:230–6.
   PubMed Web of Science ®Google Scholar
• Vaira M, Robella M, Mellano A, Sottile A, De Simone M. Iterative procedures combining cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for isolated peritoneal recurrence. Int J Hyperthermia 2014;30:565–9.
   PubMed Web of Science ®Google Scholar
• Rettenmaier MA, Mendivil AA, Abaid LN, Brown JV III, Wilcox AM, Goldstein BH. Consolidation hyperthermic intraperitoneal chemotherapy and maintenance chemotherapy following laparoscopic cytoreductive surgery in the treatment of ovarian carcinoma. Int J Hyperthermia 2015;31:8–14.
   PubMed Web of Science ®Google Scholar
• Heijkoop ST, van Doorn HC, Stalpers LJA, Boere IA, van der Velden J, Franckena M, et al. Results of concurrent chemotherapy and hyperthermia in patients with recurrent cervical cancer after previous chemoradiation. Int J Hyperthermia 2014;30:6–10.
   PubMed Web of Science ®Google Scholar